NEO TECT KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEO TECT KIT (NEO TECT KIT).
The drug Neo Tect Kit (technetium Tc 99m depreotide) is a radiolabeled somatostatin analog that binds to somatostatin receptors (subtypes 2, 3, and 5) expressed on various neuroendocrine tumor cells. After intravenous injection, the radiotracer accumulates in receptor-positive tissues, enabling scintigraphic imaging of somatostatin receptor-positive tumors.
| Metabolism | Technetium Tc 99m depreotide is not metabolized; it is excreted primarily via the renal system with a half-life of approximately 2.5 hours. The radioactive decay of technetium-99m (half-life 6 hours) occurs through isomeric transition. |
| Excretion | Renal: >95% within 48 hours; minimal biliary/fecal (<2%) |
| Half-life | Terminal half-life: 72 hours; allows single-dose imaging for up to 24 hours post-injection |
| Protein binding | >95% bound to human serum albumin (HSA) |
| Volume of Distribution | 0.12 L/kg; reflects limited distribution mainly to blood pool and injection site |
| Bioavailability | IV: 100% |
| Onset of Action | IV: Within 30 minutes for sentinel lymph node detection; optimal imaging 2-4 hours post-injection |
| Duration of Action | IV: Imaging quality persists for 24 hours; clinical utility for lymphoscintigraphy up to 24 hours |
For sentinel lymph node detection: 0.5-2.0 mCi (18.5-74 MBq) technetium Tc-99m labeled, administered as 0.1-0.5 mL intradermally, subcutaneously, or peritumoral injection, with imaging within 2-4 hours. For lymphoscintigraphy: 0.5-1.0 mCi injected subdermally or subcutaneously in divided doses. Dose and route depend on clinical protocol.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; technetium Tc-99m is excreted renally, but standard doses are low (<2 mCi) and not systemically active. |
| Liver impairment | No dose adjustment required for hepatic impairment; technetium Tc-99m is not metabolized by liver. |
| Pediatric use | Children: 0.01-0.02 mCi/kg (0.37-0.74 MBq/kg) subcutaneously or intradermally, with a minimum dose of 0.1 mCi. Maximum dose may not exceed adult dose. Imaging at 1-2 hours post-injection. |
| Geriatric use | No specific dose adjustment; use lowest effective dose per standard protocol, considering comorbidities and potential for injection site reactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEO TECT KIT (NEO TECT KIT).
| Breastfeeding | Tc 99m is excreted into breast milk. The M/P ratio is not established. After administration, breastfeeding should be interrupted for 24-48 hours to minimize infant radiation exposure. Advise pumping and discarding milk during this period. |
| Teratogenic Risk | NEO TECT KIT contains technetium Tc 99m and is used for diagnostic imaging. Radiopharmaceuticals, including Tc 99m, are associated with a risk of fetal harm due to radiation exposure. During the first trimester, the risk of teratogenesis is highest, with potential for major malformations. In the second and third trimesters, there is increased risk of growth restriction and neurodevelopmental effects. Use only if clearly needed and the benefit outweighs the risk. |
■ FDA Black Box Warning
No FDA black box warning has been issued for Neo Tect Kit. However, as a radioactive diagnostic agent, it carries inherent risks of radiation exposure and allergic reactions.
| Serious Effects |
["Known hypersensitivity to technetium Tc 99m depreotide or any component of the kit.","Pregnancy (unless benefit outweighs risk; consider alternative imaging).","Lactation (discontinue breastfeeding for at least 24 hours after administration)."]
| Precautions | ["Risk of allergic reactions including anaphylaxis; emergency resuscitation equipment should be available.","Radiation exposure: The use of radioactive products must be minimized, especially in pregnant women and children.","False-positive results may occur due to uptake in inflammatory lesions or non-neoplastic conditions.","False-negative results may occur in tumors with low somatostatin receptor density or receptor heterogeneity.","Renal impairment may alter biodistribution and increase radiation dose.","Patients should be well-hydrated and encouraged to void frequently after administration to reduce bladder radiation dose."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs and fetal heart rate during and after the procedure. Assess for signs of allergic reaction. Document radiation exposure and ensure pregnancy status is confirmed before administration. |
| Fertility Effects | No known direct effects on fertility. However, gonadal radiation exposure from Tc 99m may theoretically impact fertility, particularly with repeated doses. Women should be counseled on potential risks. |